Business Wire

New Ferring and Aché Laboratórios Farmacêuticos Facility Opens to Optimise Drug Delivery Using Nanotechnology

Jaa

Ferring Pharmaceuticals and Aché Laboratórios Farmacêuticos today announced the inauguration of their joint nanotechnology centre in São Paulo, Brazil. Focused exclusively on nanotechnology research and development, the centre forms the first phase in a long term collaboration to optimise patient care through enhanced drug delivery systems and product solutions.

The Nanotechnology Innovation Laboratory Enterprise (NILE) centre and associated research programme will explore nanotechnology to advance the delivery characteristics of existing medicines, create novel devices and find new formulations for poorly soluble drugs. For example, for patients who currently receive treatment by injection, this new technology has the potential to transform their ongoing care with new oral options. Researchers will investigate how nanotechnology might improve the bioavailability, efficacy and safety profile of oral medicines, and alleviate any unwanted toxicity resulting from non-specific distribution.

Initial research projects will utilise each company’s therapeutic strengths. Ferring will provide expertise on peptides and proteins in reproductive medicine and women’s health, gastroenterology and urology, and Aché will provide knowledge on how to expedite the development of new therapeutic entities with different technical properties.

“Using nanotechnology to administer peptide and protein-based medicines orally could be a significant step forward for the ease of delivery for this important class of drugs,” said Alan Harris, Senior Vice President, R&D, Ferring Pharmaceuticals. “Ferring’s pioneering work in reproductive medicine and women’s health is devoted to providing next generation solutions that improve outcomes and better serve the needs of our patients. If we can provide patients with more convenient dosing, we will help to improve adherence and ensure that patients receive the greatest benefit from treatment.”

“In recent years, considerable investment has been made in Brazil to harness the potential of nanotechnology. Our established strength in using radical innovation to create new assets, whether synthetic, herbal, biologicals or nutraceuticals, combined with the rich source of natural compounds existing within Brazilian biodiversity, places us in a unique position to lead future cutting-edge science,” said Stephani Saverio, head of Innovation of Aché. “Nanotechnology has huge potential to address the challenges associated with today’s drug delivery systems and to optimise future care.”

The NILE centre is anticipated to be a global hub for future drug discovery and development. The inauguration ceremony brought together leading experts from the field of nanotechnology as well as dignitaries from the Ministry of Health of Brazil and government officials.

- Ends -

About Nanotechnology
Nanotechnology is a branch of technology focused on understanding and controlling matter at the very smallest scales. At nanoscale, properties can be very different when compared to those with which we are familiar. Such properties mean that nanotechnology has the potential to optimise current drug delivery technologies, and offers many opportunities to create new drug delivery systems, formulations for poorly soluble drugs and novel devices. In addition to the potential advantages of enhancing systemic administration, nanoparticulate drug delivery systems can also be used for site-specific delivery, thus alleviating unwanted toxicity due to nonspecific distribution, helping to improve patient compliance and provide favourable clinical outcomes. Nanotechnology platforms will help in the development of advanced drug-delivery systems to decrease the failure rate of new active pharmaceutical ingredients (APIs), bio-therapeutic agents and vaccines caused by poor absorption, or distribution, significant drug toxicity, and rapid metabolism or excretion.

About Ferring Pharmaceuticals:
Headquartered in Saint-Prex, Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. A leader in reproductive and maternal health, Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative treatments to help mothers and babies, from conception to birth. The company also identifies, develops and markets innovative products in the areas of urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. For further information on Ferring or its products, visit www.ferring.com.

Ferring is on Twitter. Follow us @FerringNews at http://twitter.com/FerringNews

About Aché Laboratórios Farmacêuticos
Aché is a 100% Brazilian company with more than 50 years of operation in the pharmaceutical market with the objective of bringing more life to the persons, wherever they are. It has three industrial sites: Guarulhos (SP), São Paulo (SP), and Londrina (PR), and participation in Melcon do Brasil, and Bionovis, a Brazilian joint venture dedicated to research and development of biotechnology medicines. It employs 4,600 people and has one of the largest demand and sales generation forces in the pharmaceutical sector in Brazil. In order to meet the needs of healthcare professionals and consumers, Aché offers a portfolio of 326 brands in 804 submissions for prescription, generic and OTC (non-prescription) drugs, and it also acts in the segments of skin cosmetics, nutraceuticals, probiotic and biological segments. Ache´s focus on innovation has been developing attractive products currently present in 20 countries of the Americas, Africa, and Asia. Ache´s innovative products are being developed for registration in the world´s most regulated markets. To know more about Aché, please visit www.ache.com.br.

Contact information

Ferring Corporate Communications Team:
Lindsey Rodger
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
lindsey.rodger@ferring.com
or
Bhavin Vaid
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)
bhavin.vaid@ferring.com
or
For Aché Laboratórios Farmacêuticos
Press Information:
CDI Corporative Communication
Renata Lopes
+55 (11) 3817-7994
renata.lopes@cdicom.com.br
or
Flavia Tavares
+55 (11) 3817-7914
flavia@cdicom.com.br
or
Cláudia Santos
+55 (11) 3817-7925
claudia@cdicom.com.br

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Takeda and the New York Academy of Sciences Announce 2019 Innovators in Science Award Winners12.12.2018 16:00Tiedote

Takeda Pharmaceutical Company Limited, (“Takeda”) (TSE:4502) and the New York Academy of Sciences announced today the Winners of the second annual Innovators in Science Award for their commitment to and excellence in regenerative medicine. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181212005061/en/ The 2019 Winner of the Senior Scientist Award is Michele De Luca, M.D., Professor of Biochemistry and Director of the Centre for Regenerative Medicine “Stefano Ferrari”, University of Modena and Reggio Emilia in Modena, Italy. Dr. De Luca has dedicated his career in translational medicine to developing stem cell therapies and is a leading authority on human squamous epithelial stem cell biology. “Breakthroughs in regenerative medicine start with basic science and developmental biology. It’s an honor to be recognized for my research in epithelial stem cells and for my contributions in expanding their therapeutic potential,” sai

Wipro Achieves ‘Cloud Elite’ Status in Oracle PartnerNetwork Cloud Program12.12.2018 15:40Tiedote

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it has achieved the ‘Cloud Elite’ status in the Oracle PartnerNetwork (OPN) Cloud Program. The Oracle Cloud Elite status is conferred upon highly skilled Oracle partners who have managed multiple cloud implementations for clients across the globe in the Software as a service (SaaS), Platform as a Service (PaaS) and Infrastructure as a service (IaaS) space. Typically, these are companies that have demonstrated strong cloud delivery capabilities, have been endorsed by their customers, and have a significant pool of resources skilled in technologies related to Oracle Cloud. Ravi Purohit, Vice President & Global Head – Oracle service line, Modern Application Services, Wipro Limited said, “We are proud of how our relationship with Oracle has grown and gone from strength to strength, over the years. The Oracle Cloud Elite status i

SailPoint Releases Industry’s First Identity Annual Report12.12.2018 15:00Tiedote

SailPoint Technologies Holdings, Inc. (NYSE: SAIL), the leader in enterprise identity governance, today released the 2018 Identity Report, the industry’s first benchmark. In 2017, SailPoint launched a free assessment tool to help identify areas of exposure for companies, which automatically computed an “Identity Score” based on its results. After analyzing hundreds of completed self-assessments and the correlating Identity Scores, SailPoint found that while the majority of organizations have an identity program in place, there is still much work to be done to address holes in their security programs. To download the report, please visit https://www.sailpoint.com/IdentityReport “IT leaders are struggling to secure an increasingly complex IT environment, driven by the need to govern a diverse population of users, now including non-human users like software bots, as well as an explosion of both applications and data,” said Kari Hanson, Vice President of Corporate Marketing, SailPoint. “Ou

LTI Appoints Nachiket Deshpande as Chief Operating Officer12.12.2018 14:00Tiedote

Larsen & Toubro Infotech (BSE: 540005, NSE: LTI), a global technology consulting and digital solutions company, has appointed Nachiket Deshpande as its Chief Operating Officer. Nachiket brings more than 23 years of rich experience in delivery management, customer relationships management, account and P&L management across verticals, technologies and geographies. In his last role as the Senior Vice President & Global Delivery Head for the Banking and Financial Services unit at Cognizant Technology Solutions, he was responsible for global delivery and P&L across all services lines, products, and platforms, as well as driving large-scale skills transformation. In a career spanning more than two decades, he has held management positions in the US, Europe, and Asia across delivery, practice building and client facing roles. Sanjay Jalona, Chief Executive Officer & Managing Director, LTI, said, “Nachiket joins us at an exciting phase of LTI’s transformation as customers entrust us with solvi

ABB: Statement12.12.2018 13:25Tiedote

ABB confirms that it is currently in discussions with Hitachi to expand and re-define the existing strategic power grid partnership between the two companies announced in December 2014. There can be no certainty that any transaction will occur, or as to the timing, structure or terms of any transaction. This information is information that ABB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 11:00 CET on December 12, 2018. ABB (ABBN: SIX Swiss Ex) is a pioneering technology leader in power grids, electrification products, industrial automation and robotics and motion, serving customers in utilities, industry and transport & infrastructure globally. Continuing a history of innovation spanning more than 130 years, ABB today is writing the future of industrial digitalization with two clear value propositions: bringing electricity from any power plant to any plug a

Amazon Web Services Launches New Region in Sweden12.12.2018 11:36Tiedote

Amazon Web Services, Inc. (AWS), an Amazon.com company (NASDAQ:AMZN), today announced the opening of the AWS Europe (Stockholm) Region. With this launch, AWS now provides 60 Availability Zones across 20 infrastructure regions globally, with another 12 Availability Zones and four regions in Bahrain, Hong Kong SAR, Italy, and South Africa all coming online by the first half of 2020. The AWS Europe (Stockholm) Region is AWS’s fifth in Europe, joining existing regions in France, Germany, Ireland, and the UK. Tens of thousands of customers across the Nordics – Denmark, Finland, Iceland, Norway, and Sweden – already use AWS. Starting today, developers, startups, and enterprises, as well as government, education, and non-profit organizations can leverage the new AWS Europe (Stockholm) Region to run their applications in Sweden, serve end-users across the Nordics with lower latency, and leverage advanced technologies such as analytics, database, mobile services, serverless, and more, to drive

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme